FDA Approved: JADENU — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approves a supplemental application for JADENU (deferasirox) from Novartis, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Beta-thalassemia
• Iron Overload
• Myelodysplastic Syndrome
• Transfusion-dependent Anemia

Drugs mentioned

• JADENU (deferasirox)

Snippet

SUPPL AP for JADENU (DEFERASIROX)